Phathom Pharmaceuticals, Inc.
PHAT
$14.75
$0.010.03%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 25.32% | 38.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 25.32% | 38.51% | |||
| Cost of Revenue | 22.87% | 35.28% | |||
| Gross Profit | 25.68% | 39.00% | |||
| SG&A Expenses | -39.57% | -9.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -34.85% | -7.41% | |||
| Operating Income | 74.52% | 24.02% | |||
| Income Before Tax | 60.46% | 19.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 60.46% | 19.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 60.46% | 19.62% | |||
| EBIT | 74.52% | 24.02% | |||
| EBITDA | 74.70% | 24.06% | |||
| EPS Basic | 60.96% | 20.18% | |||
| Normalized Basic EPS | 60.97% | 20.18% | |||
| EPS Diluted | 60.96% | 20.18% | |||
| Normalized Diluted EPS | 60.97% | 20.18% | |||
| Average Basic Shares Outstanding | 1.28% | 0.69% | |||
| Average Diluted Shares Outstanding | 1.28% | 0.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||